Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III, Double-Blind, Randomized, Placebo-Controlled, Multicenter, International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema

NCT01217671 is registered in ClinicalTrials.gov with Kamada, Ltd. as lead sponsor.

NCT NCT01217671
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01217671 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III, Double-Blind, Randomized, Placebo-Controlled, Multicenter, International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema
Lead sponsor
Kamada, Ltd.
Phase
Phase 2/3
Overall status
Completed
Start date
December 31, 2009
Completion date
June 30, 2015
Enrollment
168 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

emphysema